Clinical applications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary

Chinese Medical Journal

Volumn 124, Issue 7, 2011, Pages 1010-1014

  Hu, Man ^a   Zhao, Wei ^a   Zhang, Pin Liang ^a   Ju, Gui Fang ^a   Fu, Zheng ^a   Zhang, Guo Li ^a   Kong, Li ^a   Yang, Yan Qin ^a   Ma, Yi Dong ^a   Yu, Jin Ming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

18F fluorodeoxyglucose positron emission tomography computed tomography; Carcinoma of unknown primary

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; BILE DUCT TUMOR; BONE METASTASIS; BREAST CARCINOMA; BREAST TUMOR; CANCER OF UNKNOWN PRIMARY SITE; COLON POLYP; COLON TUMOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; ESOPHAGUS TUMOR; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HYPERPLASIA; HUMAN; KIDNEY TUMOR; LARYNX TUMOR; LIVER METASTASIS; LIVER TUMOR; LUNG ADENOCARCINOMA; LUNG GRANULOMA; LUNG METASTASIS; LUNG MYCOSIS; LUNG TUBERCULOSIS; LUNG TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX INFLAMMATION; NASOPHARYNX TUMOR; OCCULT CANCER; OVARY TUMOR; PANCREAS TUMOR; PAROTID GLAND TUMOR; PERITONEUM METASTASIS; PHARYNX DISEASE; PLEURA METASTASIS; PRIMARY TUMOR; PROSTATE TUMOR; RECTAL GRANULOMA; RECTUM TUMOR; SALIVARY GLAND DISEASE; SALIVARY GLAND TUMOR; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; SUBMANDIBULAR GLAND INFLAMMATION; THYROID TUMOR; THYROIDITIS; TONSIL TUMOR; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; UTERUS TUMOR; WHOLE BODY CT; WHOLE BODY PET; CARCINOMA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REPRODUCIBILITY;

ADULT; AGED; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 79954507185     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.07.011     Document Type: Article

References (22)

1. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009; 69: 271-278.
2. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329: 257-263.
3. Yuan S, Yu J, Chao KS, Fu Z, Yin Y, Liu T, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 2006; 47: 1255-1259.
4. Liu BJ, Dong JC, Xu CQ, Zuo CT, Le JJ, Guan YH, et al. Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers. Chin Med J 2009; 122: 1749-1754.
5. Roedl JB, Prabhakar HB, Mueller PR, Colen RR, Blake MA. Prediction of metastatic disease and survival in patients with gastric and gastroesophageal junction tumors: the incremental value of PET-CT over PET and the clinical role of primary tumor volume measurements. Acad Radiol 2009; 16: 218-226.
6. Macapinlac HA. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 2008; 38: 137-140.
7. Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006; 50: 15-22.
8. Basu S, Alavi A. FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies. Eur J Nucl Med Mol Imaging 2007; 34: 427-428.
9. Kolesnikov-Gauthier H, Levy E, Merlet P, Kirova J, Syrota A, Carpentier P, et al. FDG PET in patients with cancer of an unknown primary. Nucl Med Commun 2005; 26: 1059-1066.
10. Hu M, Li MH, Kong L, Liu NB, Yang GR, Yu JM. (18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin. Chin J Oncol (Chin) 2008; 30: 699-701.
11. Wu ZJ, Zhang YX, Wei H, Jia Q. The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors. Natl Med J China (Chin) 2007; 87: 2253-2256.
12. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977; 4: 53-58.
13. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292-299.
14. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 2009; 19: 731-744.
15. Song H, Yu JM, Kong FM, Lu J, Bai T, Ma L, et al. [18F]2-fluoro-2-deoxyglucose positron emission tomography/computed tomography in predicting radiation pneumonitis. Chin Med J 2009; 122: 1311-1315.
16. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412-1417.
17. Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003; 70: 500-506.
18. Liu ZY, Chang ZH, Lu ZM, Guo QY. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful? Chin Med J 2010; 123: 1690-1694.
19. Lan XL, Zhang YX, Wu ZJ, Jia Q, Wei H, Gao ZR. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol 2008; 63: 756-764.
20. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual-time-point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43: 871-875.
21. Bohuslavizki KH, Klutmann S, Kröger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-822.
22. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 10: 2641-2649.